Panbela Therapeutics Umsatz

Was ist das Umsatz von Panbela Therapeutics?

Umsatz von Panbela Therapeutics Inc. ist $0.00

Was ist die Definition von Umsatz?



Umsatz sind die Einnahmen, die ein Unternehmen aus seiner normalen Geschäftstätigkeit erzielt, normalerweise aus dem Verkauf von Waren und Dienstleistungen an Kunden.

Revenue is also referred to as sales or turnover. Some companies receive revenue from interest, royalties, or other fees. Revenue may refer to business income in general, or it may refer to the amount, in a monetary unit, earned during a period of time, as in "Last year, Company X had revenue of $42 million". Profits or net income generally imply total revenue minus total expenses in a given period.

In accounting, revenue is often referred to as the "top line" due to its position on the income statement at the very top. This is to be contrasted with the "bottom line" which denotes net income.

Umsatz von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Panbela Therapeutics

Was macht Panbela Therapeutics?

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.

Unternehmen mit umsatz ähnlich Panbela Therapeutics